Outlook Therapeutics Engages in Key Eye Health Conference
ISELIN, N.J. – Outlook Therapeutics, Inc. (Nasdaq: OTLK), a trailblazing biopharmaceutical firm, recently participated in the 2nd Annual Chardan Virtual Ophthalmology Conference Series. This important event concentrates on age-related macular degeneration (AMD) and diabetes-related eye diseases, bringing together leaders in the industry who are focused on tackling significant challenges in eye health.
Conference Highlights
This year's conference showcased eight innovative companies, each detailing their distinctive strategies for tackling debilitating eye conditions, with a strong emphasis on AMD, a leading cause of vision impairment among adults. Outlook Therapeutics made a notable impact at the event, as its President and CEO, Russell Trenary, along with Chief Executive Officer Lawrence Kenyon, fully participated. Their insights were shared during an engaging fireside chat, facilitated by Daniil Gataulin, PhD, a Senior Research Analyst from Chardan.
Fireside Chat Insights
The fireside chat provided a thorough exploration of Outlook Therapeutics’ mission and the advanced solutions they’re working on. The conversation particularly highlighted their recently approved ophthalmic formulation of bevacizumab, named LYTENAVA™ (bevacizumab gamma), showcasing the company’s dedication to meeting the unmet needs in treating retinal diseases.
About LYTENAVA™ (bevacizumab gamma)
LYTENAVA™ marks a significant advancement as the first ophthalmic formulation of bevacizumab authorized for marketing by regulatory agencies in both the EU and the UK. This product is expected to be commercially available in these regions in early 2025, representing a major milestone in the fight against wet AMD.
Clinical Trials and Future Prospects
In the United States, LYTENAVA™ is still under evaluation as part of an ongoing non-inferiority study. This study aims to demonstrate its effectiveness compared to existing treatments for wet AMD. Should this trial prove successful, Outlook Therapeutics may look to resubmit a Biologics License Application (BLA) to the FDA, potentially leading to the first approved ophthalmic formulation of bevacizumab for retinal issues in America. This progress could create new treatment pathways for patients struggling with wet AMD.
Investor Relations and Communication
As Outlook Therapeutics pursues its commitment to enhancing eye health, it's vital for investors to have an open line of communication. For any inquiries about the company’s initiatives, investors can contact Jenene Thomas, the Chief Executive Officer of JTC Team, LLC. She’s available at 833.475.8247 or via email at OTLK@jtcir.com.
Frequently Asked Questions
What is Outlook Therapeutics known for?
Outlook Therapeutics specializes in developing and commercializing innovative treatments for retinal diseases, with its flagship product being LYTENAVA™.
What is the significance of the 2nd Annual Chardan Virtual Ophthalmology Conference?
This conference promotes collaboration among industry leaders to advance treatments and innovations specifically targeting age-related macular degeneration and related ocular diseases.
When is LYTENAVA™ expected to launch in the EU and UK?
The commercial introduction of LYTENAVA™ is anticipated in the first half of 2025, representing a vital addition to the available treatment options for AMD.
How does LYTENAVA™ compare to other treatments?
LYTENAVA™ is the first ophthalmic formulation of bevacizumab that’s been approved in Europe for wet AMD, marking a unique treatment efficacy that hasn’t yet been replicated by other products in this area.
How can investors get in touch with Outlook Therapeutics?
Investors wishing to reach out can contact Jenene Thomas at JTC Team, LLC, at 833.475.8247 or via email at OTLK@jtcir.com for questions regarding company performance and initiatives.
